ArticleJNCI cancer spectrum2026
Late effects among colorectal cancer survivors ≥5 years after diagnosis-a systematic scoping review.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) survival is improving, yet long-term survivors remain at risk for cancer- and treatment-related late effects, which may emerge many years after diagnosis and treatment. We aimed to summarize evidence on late effects and their risk factors reported ≥5 years after CRC diagnosis, compared to cancer-free controls.
methodsThe literature search for this scoping review was conducted in PubMed, EMBASE, and Web of Science from inception to November 18, 2025. Primary research studies investigating late effects and providing relative risk estimates specifically ≥5 years after diagnosis were included. Risk of bias was assessed with the Newcastle-Ottawa-Scale. The study was registered with Open Science Framework, 10.17605/OSF.IO/JY6DX.
resultsWe identified 9 observational studies that reported relative risk estimates for late effects. Seven studies had a low risk of bias and 2 were at moderate risk. The most frequently investigated late effect was incidence of diabetes (5 studies). The highest relative risks were reported for immunity disorders (5-10 years hazard ratio [HR] = 4.56, 99% CI = 1.36 to 15.31), depression (>5 years HR = 2.65, 95% CI =1.61 to 4.36), and nutritional deficiency (5-10 years HR = 1.69, 99% CI = 1.38 to 2.08). Comorbidities at diagnosis, age at diagnosis, and treatment were the most common risk factors associated with late effects.
conclusionsThis scoping review found that even ≥5 years after diagnosis late effects requiring treatment are considerably more common among CRC survivors than cancer-free controls. The small number of studies and the broad spectrum of identified late effects highlight the need for extensive research to characterize late effects to improve long-term survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.